- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02193256
Varenicline + Prazosin for Heavy Drinking Smokers
Pilot Trial of Varenicline and Prazosin to Treat Heavy Drinking Smokers
The purpose of this study is to examine the effect of varenicline and prazosin on smoking, drinking, and sleep among cigarette smokers who report heavy alcohol use. Varenicline is an FDA approved smoking cessation medication. Some smokers report sleep problems when taking varenicline. This study will test whether using prazosin, which is an FDA-approved blood pressure medication, in combination with varenicline reduces sleep problems that can be associated with using varenicline for smoking cessation. In addition, the study will examine the combined effects of these medications on smoking and drinking.
Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone prior to the 3-day practice quit attempt.
Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone during the 3-day practice quit attempt.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study comprises an 8-week double-blind, within-subjects, crossover design of varenicline (up to 2mg per day) plus either prazosin (up to 8mg per day) (V+P) or placebo (V) with 20 heavy drinking smokers. Each medication phase is 3 weeks with a 2-week medication washout in between. Participants are asked to make a practice quit attempt for 3 days the last week of each medication phase.
This is an exploratory study to look at two primary aims:
Evaluate the effect of prazosin on sleep disturbance caused by varenicline in heavy drinking smokers prior to quitting smoking.
Hypothesis: V+P will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than V alone.
- Evaluate the effect of prazosin on sleep disturbance caused by varenicline during smoking cessation in heavy drinking smokers.
Hypothesis: V+P will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than V alone We will also investigate the combined effects of prazosin and varenicline on smoking behavior (i.e., smoking urge) and alcohol consumption (i.e., drinks per drinking day) as exploratory aims.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- at least 18 years of age;
- current smoker [quantity of ≥ cigarettes per smoking day, frequency of ≥3 times per week, and urinary cotinine ≥2 on NicAlert dipstick;
- at least 4 occasions of heavy drinking in the past 30 days [5 or 4 standard drinks per occasion for males and females, respectively];
- no history of severe alcohol withdrawal syndrome;
- no new onset of psychiatric illness or psychotropic medications in last 90 days;
- no severe psychiatric illness [schizophrenia, bipolar disorder] or PTSD;
- no substance dependence other than nicotine, alcohol or marijuana;
- no medical contraindications for varenicline or prazosin;
- are willing to take medication and wear portable sleep monitoring devices;
- no risk for sleep apnea syndrome;
- able to read and write in English;
- not interested in quitting smoking immediately.
Exclusion Criteria:
- unable to complete the informed consent;
- do not meet criteria for heavy drinking;
- do not meet criteria for current smokers;
- unable to read/understand English;
- exhibit serious psychiatric illness (i.e. schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder), organic mood or mental disorders by history of psychological examination;
- meet criteria for alcohol dependence in past 12 months that is clinically severe;
- meet criteria for drug dependence in the last 12 months aside from marijuana, nicotine and alcohol;
- are seeking to quit smoking immediately;
- report current psychosis or suicidality;
- are a female of childbearing potential who is pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide);
exhibit current, clinically significant physical disease or abnormality based on medical history, physical examination, or routine laboratory evaluation including:
- any unexplained elevations in liver enzymes (i.e. transaminases, bilirubin);
- clinically significant, unstable cardiovascular disease/uncontrolled hypertension;
- hepatic or renal impairment;
- severe obstructive pulmonary disease;
- diabetes mellitus requiring insulin or certain oral medications (i.e. sulfonylureas) and an A1C hemoglobin test score of >7 for participants not prescribed these medications;
- baseline systolic blood pressure higher than 150 mm Hg of diastolic blood pressure higher than 95 mm Hg; (g) are scheduled for cataract surgery; (h) have a diagnosis of narcolepsy;
- have a history of cancer (except treated basal cell or squamous cell carcinoma of the skin)
- have a history of clinically significant allergic reactions;
- have used any psychotropic drug in the past month, except individuals who are on a stable dose of a Selective Serotonin Reuptake Inhibitor for at least two months;
- intend to donate blood or blood products during the treatment phase of the study;
- have a Body Mass Index (calculated as weight in kilograms divided by the square of height in meters) less than 15 or greater than 28 or weight less than 45 kg.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Varenicline plus Prazosin
Varenicline: .5mg
for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3).
Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
|
Titrated over 1 week to a maximum dose of 2mg/day
Other Names:
Titrated over 3 weeks to a maximum dose of 8mg/day
Other Names:
|
Placebo Comparator: Varenicline plus Placebo
Varenicline: .5mg
for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3).
Placebo: placebo will be given instead of prazosin (Weeks 1-3)
|
Titrated over 1 week to a maximum dose of 2mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of prazosin on sleep disturbance caused by varenicline prior to quitting smoking
Time Frame: Two weeks
|
Sleep disturbance will be measured using self-report questionnaires (Insomnia Severity Index, Pittsburgh Sleep Quality Index, Pittsburgh Sleep Diary, Dream Quality Questionnaire) and objective sleep-monitoring devices.
|
Two weeks
|
Effect of prazosin on sleep disturbance caused by varenicline during smoking cessation
Time Frame: One week
|
Sleep disturbance will be measured using self-report questionnaires (Insomnia Severity Index, Pittsburgh Sleep Quality Index, Pittsburgh Sleep Diary, Dream Quality Questionnaire) and objective sleep-monitoring devices.
|
One week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of cigarettes smoked
Time Frame: Three weeks
|
The investigators will compare the combined effects of prazosin and varenicline on the number of cigarettes smoked with varenicline alone.
|
Three weeks
|
Number of drinks per drinking day
Time Frame: Three weeks
|
The investigators will compare the combined effects of prazosin and varenicline on alcohol consumption (i.e., number of drinks per drinking day) with varenicline alone as an exploratory aim.
|
Three weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lisa M Fucito, PhD, Yale University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcoholism
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Cholinergic Agents
- Nicotinic Agonists
- Cholinergic Agonists
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Varenicline
- Prazosin
Other Study ID Numbers
- 1402013410
- K05AA014715 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorders
-
University of Colorado, DenverUnknownAlcohol Use Disorders | Unhealthy Alcohol UseUnited States
-
Women's College HospitalRecruitingAlcohol; Harmful Use | Tobacco Use | Tobacco Use Cessation | Alcohol Use, UnspecifiedCanada
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
University of Southern DenmarkCompleted
-
Karolinska InstitutetGöteborg UniversityCompletedAlcohol Use DisordersSweden
-
University of VirginiaCompletedAlcohol Use DisordersUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States